Trial Profile

A phase III trial assessing GBS-007 in patients with age-related macular degeneration

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Age-related macular degeneration
Focus Registrational; Therapeutic Use
Sponsors Gene Techno Science; Kidswell Bio

Most Recent Events

22 Mar 2022 According to a Kidswell Bio Corporation website, the Gene Techno Science has changed its name to Kidswell Bio Corporation effective from 1 July 2021.
19 Feb 2020 Status changed from active, no longer recruiting to completed, according to a Gene Techno Science media release.
06 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com